Intratonsillar Immunotherapy for Allergic Rhinitis

Inclusion Criteria: * Voluntarily sign informed consent. * Commitment to follow the research procedures and cooperate with the implementation of the entire research process. * Diagnosis in accordance with ARIA guidelines, based on: ① Symptoms: Two or more symptoms such as paroxysmal sneezing, watery nose, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day. May be accompanied by eye symptoms such as tearing, eye itching, and eye redness. ② Signs: Common nasal mucosa pale, edema, nasal watery secretions. * Allergen test: Positive for skin prick test (SPT) and/or serum-specific IgE for at least one allergen, or positive for nasal provocation test. * Have a history of allergic rhinitis caused by atopic allergens and one of the following: ① No significant relief after drug treatment. ② Do not want to continue taking medication for a long time. ③ Long-term drug treatment can produce adverse side effects. * Allergens cannot be effectively avoided in daily life. * Women of childbearing age must ensure that they do not become pregnant during the treatment cycle. * Must be between 5 and 65 years old. Exclusion Criteria: * Allergic to the excipient (aluminum hydroxide) of Allergopharma or the rescue medication epinephrine. * Respiratory disease other than stable asthma. * Pulmonary insufficiency (NYHA grade II and above or FEV1 \< 80%) or irreversible changes in the responding organs such as emphysema and bronchi…